Apop Imaging has been awarded a CSIRO kick start grant to optimise its product manufacture. Working with expert teams at CSIRO Parkville and Clayton sites, this grant will prepare the company for product launch. In addition, new market research has identified an application of our biomedical research reagents in a market without a serious competitor.
About Apop Imaging:
In biomedical research, there is increased demand for researching Programmed Cell Death (PCD). PCD is associated with significant human diseases such as cancer, heart disease, neurodegenerative diseases and viral infections. Our first product is a novel biomedical tool to advance the discovery of new therapeutics and diagnostics for these diseases.
There are two major forms of PCD: apoptosis and autophagy. Currently, there is no straight forward way for researchers to detect autophagy. Our first product, CalRexin:568, is the only reagent that detects both forms of PCD. Apop Imaging is diversifying CalRexin reagents to meet the market of $200 million per year, which reflects the strong demand.
Apop Imaging Pty Ltd is a Melbourne based biotech start up company founded to bring novel imaging tools to a global biomedical research market. Apop Imaging was registered in October 2016 and completed a seed funding round led by Geelong and Melbourne Angels in 2018. The high calibre board and management team has secured key partnerships for R&D, and the company is on track to commercialise its first product at the end of 2019.
Go to Company Profile for: Apop Imaging
Announcement Contact: [email protected]